AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Anika to Showcase Regenerative Medicine and Orthobiologics Portfolio at the 12th Biennial International Society of Arthroscopy, Knee Surgery and Orthopaedic Sports Medicine Congress

May 13, 2019

BEDFORD, Mass.--(BUSINESS WIRE)--May 13, 2019--Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on its proprietary hyaluronic acid (“HA”) technology, today announced plans to showcase its regenerative medicine and orthobiologics portfolio at the 12th Biennial International Society of Arthroscopy, Knee Surgery and Orthopaedic Sports Medicine (ISAKOS) Congress being held in Cancun, Mexico on May 12 – 16. Anika will be a gold sponsor of the event, which will feature a lecture session focused on HYALOFAST and CINGAL. Anika will also be exhibiting its injectable, HA-based, surgical bone repair therapy as well as CINGAL and HYALOFAST at booth #221. The Anika booth will also feature hands-on demonstrations of HYALOFAST procedures using the HYALOFAST arthroscopic virtual surgery simulator.

“We’re excited to be a gold sponsor of this year’s ISAKOS Congress and look forward to showcasing our innovative orthopedic and regenerative portfolio,” said Joseph Darling, President and Chief Executive Officer of Anika Therapeutics. “Orthopedic sports medicine and sports-related injuries are a key focus for us given our extensive treatment portfolio that spans the continuum of orthopedic care. This congress represents an important opportunity for Anika to continue to develop relationships with and gain clinical insights from orthopedic medicine thought-leaders who will be critical to the successful launch of our bone repair therapy later this year.”

The biennial ISAKOS Congress focuses on showcasing a variety of new preventative, therapeutic and surgical technique information, allowing attendees to expand their knowledge and enhance their surgical skills on sports injuries. The congress features surgical demonstrations, paper presentations, debates, lectures, symposia and instructional course lectures, as well as lunch time sessions, e-posters, and technical exhibits by notable global thought-leaders. ISAKOS boasts more than 3,000 members from over 90 countries around the world.

Below are the Anika-sponsored activities being held at the 2019 ISAKOS Congress:

Lunch Time Session: HYALOFAST: One-Step Cartilage Regeneration, and CINGAL: Combination Therapy for OA Pain
Monday, May 13, 2019
12:15 – 12:45pm
Cancun International Convention Center – Cozumel 3+4
Topics/Speakers:

  • HYALOFAST: One-Step Cartilage Regeneration
    Dr. Alberto Gobbi, OASI Bioresearch Foundation, Milano – Italy
  • CINGAL: Combination Therapy for OA Pain
    Dr. Stephen J. French, M.D., FRCS(C), Sports Med CANADA

Anika Exhibit Booth #221

  • Featuring the HA-based surgical bone repair therapy, CINGAL, and HYALOFAST
  • HYALOFAST arthroscopic virtual simulator for demonstrations on surgical application

About Anika Therapeutics, Inc.
Anika Therapeutics, Inc.  (NASDAQ: ANIK) is a global, integrated orthopedic and regenerative medicines company based in Bedford, Massachusetts. Anika is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies along the continuum of care, from palliative pain management to regenerative tissue repair. The Company has over two decades of global expertise developing, manufacturing, and commercializing more than 20 products based on its proprietary  hyaluronic acid (HA) technology. Anika’s orthopedic medicine portfolio includes  ORTHOVISC®MONOVISC®, and  CINGAL®, which alleviate pain and restore joint function by replenishing depleted HA, and  HYALOFAST, a solid HA-based scaffold to aid cartilage repair and regeneration. For more information about Anika, please visit  www.anikatherapeutics.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20190513005056/en/

CONTACT: For Investor Inquiries:

Anika Therapeutics, Inc.

Sylvia Cheung, 781-457-9000

Chief Financial OfficerFor Media Inquiries:

W2O Group

Sonal Vasudev, 917-523-1418sonal@w2ogroup.com

KEYWORD: UNITED STATES MEXICO NORTH AMERICA CENTRAL AMERICA MASSACHUSETTS

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY PHARMACEUTICAL OTHER HEALTH

SOURCE: Anika Therapeutics, Inc.

Copyright Business Wire 2019.

PUB: 05/13/2019 08:30 AM/DISC: 05/13/2019 08:30 AM

http://www.businesswire.com/news/home/20190513005056/en